INS and type 2 diabetes mellitus: Elliot et al.,59 in a recent chart review of 91 poorly controlled T2D adults (9.4% baseline HbA1c) treated with basal insulin therapy, reported significant reductions in HbA1c (−0.8%, P < 0.0001) after 3 to 6 months of isCGM use.59 Results from a subgroup analysis that compared patients with baseline HbA1c of <9.0% and >9.0% showed clinically significant reductions in the higher HbA1c group (−1.6%, P < 0.0001).